Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo

Authors: Ingunn Holen, Jacob Whitworth, Faith Nutter, Alyson Evans, Hannah K. Brown, Diane V. Lefley, Ivana Barbaric, Mark Jones, Penelope D. Ottewell

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

After the publication of this study [1] an error was detected in Fig. 2e. The same image was accidently used for beta-catenin staining of MCF7 2A-1 and T47D 2A-4. This error does not affect the findings or conclusions of the article. The corrected figure is shown below and we apologise for this mistake.
Literature
1.
go back to reference Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M, Ottewell PD. Loss of plakoglobin promotes decreased cell-cell contact, increased invasion and breast cancer cell dissemination in vivo. Breast Cancer Res. 2012;14(3):R86.CrossRefPubMedPubMedCentral Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M, Ottewell PD. Loss of plakoglobin promotes decreased cell-cell contact, increased invasion and breast cancer cell dissemination in vivo. Breast Cancer Res. 2012;14(3):R86.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo
Authors
Ingunn Holen
Jacob Whitworth
Faith Nutter
Alyson Evans
Hannah K. Brown
Diane V. Lefley
Ivana Barbaric
Mark Jones
Penelope D. Ottewell
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0835-4

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine